Insider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Sells $45,200.00 in Stock

PROCEPT BioRobotics Co. (NASDAQ:PRCTGet Free Report) CFO Kevin Waters sold 904 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $50.00, for a total transaction of $45,200.00. Following the sale, the chief financial officer now directly owns 33,523 shares of the company’s stock, valued at approximately $1,676,150. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Kevin Waters also recently made the following trade(s):

  • On Friday, February 9th, Kevin Waters sold 28,677 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $50.09, for a total transaction of $1,436,430.93.
  • On Tuesday, January 9th, Kevin Waters sold 17,310 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $45.07, for a total transaction of $780,161.70.
  • On Wednesday, December 13th, Kevin Waters sold 71,465 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $40.05, for a total transaction of $2,862,173.25.
  • On Friday, December 8th, Kevin Waters sold 6,888 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $40.02, for a total transaction of $275,657.76.
  • On Wednesday, December 6th, Kevin Waters sold 4,360 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $40.02, for a total transaction of $174,487.20.

PROCEPT BioRobotics Stock Performance

Shares of PROCEPT BioRobotics stock opened at $49.94 on Monday. The company has a current ratio of 8.91, a quick ratio of 7.89 and a debt-to-equity ratio of 0.18. PROCEPT BioRobotics Co. has a 1-year low of $24.83 and a 1-year high of $50.48. The company’s fifty day simple moving average is $44.07 and its 200-day simple moving average is $36.32.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PRCT. Amundi purchased a new position in shares of PROCEPT BioRobotics during the 4th quarter valued at $37,000. Osaic Holdings Inc. lifted its stake in shares of PROCEPT BioRobotics by 31.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,430 shares of the company’s stock valued at $51,000 after buying an additional 338 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its stake in shares of PROCEPT BioRobotics by 40.2% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,989 shares of the company’s stock valued at $70,000 after buying an additional 570 shares in the last quarter. Ronald Blue Trust Inc. purchased a new position in shares of PROCEPT BioRobotics during the 3rd quarter valued at $71,000. Finally, UBS Group AG lifted its stake in shares of PROCEPT BioRobotics by 127.9% during the 3rd quarter. UBS Group AG now owns 1,823 shares of the company’s stock valued at $75,000 after buying an additional 1,023 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PRCT shares. Truist Financial lifted their target price on shares of PROCEPT BioRobotics from $48.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. SVB Leerink initiated coverage on shares of PROCEPT BioRobotics in a research note on Monday, October 16th. They set an “outperform” rating and a $37.00 price target on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of PROCEPT BioRobotics in a research note on Monday, October 16th. Finally, Wells Fargo & Company lifted their price target on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 9th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of “Buy” and an average price target of $44.00.

Get Our Latest Report on PRCT

PROCEPT BioRobotics Company Profile

(Get Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Featured Stories

Insider Buying and Selling by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.